SIGA secures $15M contract from Canadian Department of National Defence

What happened

SIGA Technologies said Public Services and Procurement Canada awarded it a new contract for oral TPOXX on behalf of the Canadian Department of National Defence. The contract provides for purchases of up to approximately $15M by March 31, 2031, including about $9M in firm commitments.

Confirmed

Global impact / market context

The award gives SIGA a second Canadian government order for its smallpox antiviral, extending revenue visibility toward 2031. Because only about $9M is firmly committed, part of the value depends on Canada exercising options, so the near-term cash benefit is smaller than the headline amount.

Analyst inference

This follows an earlier Canadian contract worth up to about $14M awarded in April 2020, with final delivery made in 2025. The repeat order suggests Canada is restocking government-held medical countermeasures, which matters for investors judging whether SIGA's government revenue can recur.

Analyst inference

What to watch

1. SIGA disclosed that about $6M of the contract is subject to option exercise by the Canadian Department of National Defence, so watch whether those options are exercised. Confirmed
2. Investors could compare the timing of firm commitments over the first three years with delivery schedules to estimate when revenue and cash are likely to be recognized. Proposed
3. Watch whether other governments place similar orders for oral TPOXX, since repeat purchases would indicate that stockpile demand, which supports SIGA's revenue, is continuing. Analyst inference

Evidence

• seekingalpha.com